DPX-0907: Phase I start

This quarter, ImmunoVaccine plans to begin an open-label, U.S Phase I trial to evaluate 0.25 and 1 mL doses of subcutaneous DPX-0907 in about 24 patients with metastatic breast, ovarian or prostate ca...